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CRISPR/Cas9 microinjection 
in oocytes disables pancreas 
development in sheep
Marcela Vilarino1, Sheikh Tamir Rashid2,6, Fabian Patrik Suchy2, Bret Roberts McNabb3, 
Talitha van der Meulen4, Eli J. Fine2, Syed Ahsan2,6, Nurlybek Mursaliyev2, Vittorio 
Sebastiano2, Santiago Sain Diab5, Mark O. Huising4, Hiromitsu Nakauchi2 & Pablo J. Ross  1
One of the ultimate goals of regenerative medicine is the generation of patient-specific organs 
from pluripotent stem cells (PSCs). Sheep are potential hosts for growing human organs through 
the technique of blastocyst complementation. We report here the creation of pancreatogenesis-
disabled sheep by oocyte microinjection of CRISPR/Cas9 targeting PDX1, a critical gene for pancreas 
development. We compared the efficiency of target mutations after microinjecting the CRISPR/Cas9 
system in metaphase II (MII) oocytes and zygote stage embryos. MII oocyte microinjection reduced 
lysis, improved blastocyst rate, increased the number of targeted bi-allelic mutations, and resulted in 
similar degree of mosaicism when compared to zygote microinjection. While the use of a single sgRNA 
was efficient at inducing mutated fetuses, the lack of complete gene inactivation resulted in animals 
with an intact pancreas. When using a dual sgRNA system, we achieved complete PDX1 disruption. 
This PDX1−/− fetus lacked a pancreas and provides the basis for the production of gene-edited sheep as 
a host for interspecies organ generation. In the future, combining gene editing with CRISPR/Cas9 and 
PSCs complementation could result in a powerful approach for human organ generation.
One of the main challenges of human organ transplantation is donor organ availability. In vitro creation of 
human-sized organs or tissues suitable for patient transplantation has proven difficult1. Interspecies blastocyst 
complementation provides an alternative approach and is based on emptying a “developmental organ niche” in 
one species by knocking out a specific gene, or genes, critical for development of a particular organ and using 
pluripotent stem cells (PSCs) from a different species to colonize the vacant niche and generate the desired 
organ2. As a proof of principle, the possibility for intra- and interspecies blastocyst complementation has been 
demonstrated using rodent models3–5. These results raised the possibility of generating functional human tissues 
and organs within an animal species (hosts) with similar anatomy, size, and physiology to humans6. Sheep fulfill 
these criteria, although some technical concerns such as efficient generation of gene knockout animals remain to 
be addressed.
PDX1 (pancreatic and duodenal homeobox protein 1) is a Hox-type transcription factor that is involved in 
pancreas development in the mouse and rat7. Homozygous deficiency of PDX1 in mice3, rats5, and pigs8,9 results in 
absence of pancreas development. However, the function of PDX1 is uncharacterized in sheep. Recently, the rapid 
development of genetic engineering approaches such as the CRISPR/Cas9 (Clustered Regulatory Interspaced 
Short Palindromic Repeats – CRISPR associated protein) system produced an efficient system for editing spe-
cific genes in livestock animals. CRISPR/Cas9 is a protein-RNA complex with sequence-specific nuclease activ-
ity that generates a double strand break (DSB) at the target site in a very efficient manner. Binding specificity 
is achieved through base pairing of a single guide RNA (sgRNA) and target DNA sequence10. An error-prone 
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non-homologous end-joining (NHEJ) mechanism often repairs the DSB DNA in the targeted region, leading to 
potential disruption of the protein coding sequence and inactivation of the gene. Using zygote microinjection and 
the CRISPR/Cas9 system, it is possible to produce gene-modified animals in a single step11. The high efficiency 
of CRISPR/Cas9 allows generation of bi-allelic mutants by direct zygote microinjection. However, in a high pro-
portion of embryos, Cas9 exhibits a delayed activity and can result in mosaicism. It has been shown that CRISPR/
Cas9 microinjection into zygotes can result in up to five mutant alleles in the same individual, which suggests 
that Cas9 is active during early embryonic cleavage stages12. A potential alternative to decrease mosaicism is to 
introduce CRISPR/Cas9 before DNA replication in the zygote, or even before fertilization13.
In this study, we evaluated if PDX1 disruption can disable pancreas development in sheep. We studied the effi-
ciency of MII microinjection as compared to zygote microinjection. Additionally, we used a dual sgRNA system 
and we achieved PDX1 disruption as demonstrated by absence of pancreas development. Overall, we provide an 
effective and efficient approach for the production of gene-edited sheep that could be used for patient-specific 
human organ generation.
Results
CRISPR/Cas9 microinjection in MII oocytes results in improved outcomes when compared 
to zygote microinjection. We designed and produced a sgRNA targeting exon 1 of the PDX1 gene. MII 
oocytes were denuded of cumulus oocyte complexes (COCs), microinjected with Cas9 mRNA and PDX1 sgRNA, 
and parthenogenetically activated (PA) or in vitro fertilized (IVF). Presumptive zygotes were injected at 14 h post 
activation or insemination. Reduced lysis rates were observed in MII microinjected oocytes when compared to 
microinjected zygotes (2.6% (10/379) vs. 12.5% (47/376); p < 0.05). From surviving embryos, development to the 
blastocyst stage was higher in control (31.5%, 87/276) and MII-microinjected embryos (27.1%, 100/369) versus 
Figure 1. CRISPR/Cas9 microinjection of sheep oocytes and zygotes. (a) Schematic representation of 
CRISPR/Cas9 injection in sheep MII oocytes and zygotes. Presumptive embryos were in vitro cultured until 
the blastocyst stage for embryo genotyping by Sanger sequencing and mutations were determined using the 
TIDE bioinformatics package. (b) Lysis after microinjection of CRISPR/Cas9 was lower in MII oocytes than in 
zygotes. Development was higher after microinjection in MII oocytes and non-injected embryos compared to 
zygotes (*P < 0.05; **P < 0.05). (c) Sanger sequencing results from a bi-allelic and a mono-allelic mutant sheep 
blastocyst. The PAM sequence is underlined and the gRNA target region is shown in blue. Red dashes represent 
deletions. Mutation efficiency is presented in the pie chart. For MII injected oocytes they were 46% (6/13) bi-
allelic mutated blastocyst and 20% (3/15) for zygote microinjected blastocysts.
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zygote-microinjected embryos (16.1%, 53/329; p < 0.05), irrespective of embryo production method (PA or IVF) 
(Fig. 1b; Supplementary information, Table S1).
Mutation efficiency was assessed by sequencing the target region in blastocyst stage embryos. The lack of 
wild type alleles was considered a bi-allelic mutation, where both maternal and paternal alleles are mutated even 
if they may harbor different types of mutations. An embryo was considered mosaic if three or more different 
alleles were present or when the ratio of one of the alleles was higher than 66%. Results showed that 53.8% of 
MII-injected (n = 13), and 40.0% of zygote-injected (n = 15) embryos had mutations, and 46.2% (6/13) and 20.0% 
(3/15) had bi-allelic mutations, respectively (Fig. 1c; Supplementary information, Fig. S1). To further study the 
nature of the targeted mutations, we performed deep sequencing of the CRISPR/Cas9 target site on blastocysts 
derived from MII (n = 12) and zygote (n = 10) microinjected oocytes and embryos. On average we analyzed 384 
sequences per embryo (Fig. 2). We observed that 66.7% (8/12) and 60.0% (6/10) of the blastocysts microinjected 
at MII and zygote stages, respectively, had mutations. Blastocysts microinjected at MII stage had 25.0% bi-allelic 
mutations without mosaicism (3/12) as compared with 10.0% (1/10) when microinjected at the zygote stage. 
The presence of mosaicism among mutated alleles was not significantly different between groups (37.5%, 3/8; 
vs. 66.7%, 4/6 for MII and Zygotes, respectively). The average number of alleles per mutated embryo was 2.5 in 
MII microinjected oocytes compared to 3.0 in microinjected zygotes (not found to be statistically significant, 
p > 0.05). Additionally, we observed that most of the embryos with mutations had deletions whose lengths were a 
multiple of three, resulting in in-frame mutations possibly generating a functional PDX1 protein. As an example, 
oocyte E9 from MII microinjected group had a bi-allelic mutation, but allele #2 had a 30 bp in-frame deletion that 
would still allow the majority of the PDX1 protein sequence to be translated. Only embryo E8 from MII micro-
injected oocytes lacked any potentially functional allele, with one allele having a 25 bp deletion and the other a 
5 bp deletion, both of which would result in disruption of the reading frame leading to expression of a truncated 
protein. Overall, CRISPR/Cas9 microinjection into sheep oocytes and embryos was efficient at inducing targeted 
mutations, with MII microinjections resulting in less lysis but higher developmental and bi-allelic mutation rates, 
while overall mutation efficiency and the degree of mosaicism was similar to zygote microinjection. Still, the high 
proportion of mutations that did not result in putative frame-shift mutations represents a concern for inactivating 
PDX1 using this approach.
Targeting PDX1 with a single sgRNA yielded in-frame mutations. To test if PDX1 knockout would 
alter pancreas development in sheep, we made embryo transfers of blastocysts that were injected with Cas9 
mRNA and the PDX1 sgRNA at the MII stage. Sixteen injected blastocysts were transferred to 4 recipient females 
and 4 non-injected blastocysts were transferred to a recipient female (control). At day 75, 3 of the ewes that 
received the microinjected blastocysts were pregnant, from which a total of 4 fetuses were recovered. The control 
ewe with non-injected blastocysts yielded 3 fetuses (Fig. 3a and b). Genomic DNA was extracted from the tail and 
Figure 2. Deep sequencing reveals different mutations in sheep blastocysts microinjected with CRISPR/
Cas9. Alignment of next-generation sequencing data obtained from sheep blastocysts injected with CRISPR/
Cas9 targeting PDX1 at MII oocytes (a) or at Zygotes (b). Mutations with frequencies higher than 12.5% 
were considered. Frequencies of alleles are shown in the HeatMap on the right panel and the top row refers 
to the total number of reads analyzed. Insertions with respect to the reference are presented underneath the 
alignments. (c) Number of alleles in mutant embryos after CRISPR/Cas9 microinjection in MII oocytes and 
Zygote.
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liver of the collected fetuses, and the target region was amplified and sequenced. Two of the four CRISPR/Cas9 
microinjected fetuses had mutations in the PDX1 locus. TOPO-TA cloning was performed, and from the 9 clones 
sequenced in Mutant #1, only one had mutations while all 10 clones sequenced from Mutant #2 had mutations 
(Fig. 3c). Despite the lack of wild type alleles in Mutant #2, the mutated alleles did not generate a frame-shift. 
Consequently, the resultant mutant protein contained only a few different amino acids compared to the wild type 
protein and protein function was not disrupted (Fig. 3d). This result was confirmed by the presence of a pancreas 
in Mutant #2 (Fig. 3e). Furthermore, the size of the pancreas of the two mutant fetuses was within the range 
observed for controls (165 to 231 g). In summary, these results indicate that the use of our single sgRNA targeting 
PDX1 is effective for inducing mutations, but not effective for generating functional knockouts given the potential 
high rate of in frame mutations.
CRISPR/Cas9 microinjection using dual sgRNAs effectively knocks out PDX1 and pancreato-
genesis in sheep. Recently, induction of large gene deletions using CRISPR/Cas9 combined with two sgR-
NAs in pigs was demonstrated9. Based on these results we used a set of sgRNAs that when microinjected together 
are capable of inducing a 208 bp deletion in the coding region of PDX1; therefore increasing the probability 
of inactivating the PDX1 protein. Moreover, introducing a 208 bp deletion allows evaluation of mutation effi-
ciency by gel electrophoresis of the PCR products without the need for sequencing (Fig. 4a). This approach was 
highly efficient for inducing mutations when injecting MII oocytes. From 21 microinjected oocytes, 19% (4/21) 
had mono-allelic and 19% (4/21) bi-allelic deletions (Fig. 4a). To test whether dual sgRNAs targeting PDX1 can 
disrupt pancreas development, we transferred four microinjected embryos to a recipient ewe. At 4 months we 
Figure 3. Targeting PDX1 with a single sgRNA resulted in in-frame mutations. (a) Schematic representation 
of the sgRNA targeting PDX1 gene in sheep. Sheep oocytes were microinjected with Cas9 mRNA and PDX1 
sgRNA, cultured in vitro, and 16 injected blastocyst and 4 un-injected blastocysts were collected and transferred 
to 5 recipient ewes. (b) Seven fetuses (3 controls and 4 microinjected) were collected at day 75 of development 
and 2 of the microinjected fetuses had mutations. (c) Sequencing results from 9-10 colonies of each of the 
mutant fetuses after PCR and sub-cloning of the target region. Red dashes represent deletions and red letters 
insertions; insertions (+) or deletions (−) are shown to the right of each allele. The PAM sequence is underlined 
and the target region is shown in red. (d) Protein sequences of the Mutant#2 indicate that one of the mutant 
alleles only disrupted a few amino acids indicated in red, and therefore potentially active PDX1 might be 
present. (e) The pancreas was present in both mutant fetuses.
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collected the fetus (Fig. 4b) and genomic DNA was extracted. PCR and TOPO-TA cloning followed by sequenc-
ing of 10 colonies showed a large deletion in all sequenced clones (Fig. 4c). The large deletion was observed in 
genomic PCR from liver, lung, heart, kidney, muscle and spleen (Fig. 4d). This large deletion significantly altered 
the sequence of PDX1, resulting in deletion of 69 amino acids and a shift in the open reading frame resulting in 
a truncated product (Fig. 4e). Anatomic evaluation of the GI tract revealed the absence of the pancreas. Instead, 
a vestigial structure was present (Fig. 5a; Supplementary information, Fig. S2). Upon histological evaluation we 
observed the absence of islets of Langerhans (Fig. 5b). Immunofluorescence analysis confirmed the absence of 
PDX1 and insulin in PDX1-KO fetuses (Fig. 5b; Supplementary information, Fig. S3). These results demonstrate 
that, as in mice, rats and pigs, PDX1 is necessary for pancreas development in sheep. CRISPR/Cas9 combined 
with dual sgRNAs is effective for gene disruption by direct oocyte microinjection.
Discussion
Use of livestock species as hosts for human organ generation through blastocyst complementation is one of the 
main potential approaches that regenerative medicine could utilize. Since diabetes is a common disease that 
could be treated with stem cell-derived tissues, we chose to focus on pancreas development by targeting the PDX1 
gene. In agreement with previous studies, CRISPR/Cas9 was successfully used to generate target mutations in 
sheep14–22. We efficiently disrupted the PDX1 gene in sheep by altering the protein coding sequence, resulting in 
an apancreatic phenotype.
Figure 4. CRISPR/Cas9 using dual sgRNAs can effectively knockout PDX1 in sheep. (a) Schematic 
representation of the two gRNAs designed to target PDX1 loci in sheep. Dual sgRNA microinjection can induce 
a bi-allelic deletion that can be identified by PCR amplification and gel electrophoresis of the target region. 
The full-length gel is presented in the Supplementary Information. Mutation efficiency of the dual sgRNA 
microinjection is presented in the pie chart. From 21 microinjected oocytes 4 had mono-allelic and 4 had bi-
allelic deletions. (b) Two sgRNAs targeting PDX1 gene were microinjected into the MII II oocytes before IVF, 
cultured in vitro for 6 days and transfer to a recipient sheep. The fetus was collected at 4 months of gestation. (c) 
Genomic DNA was isolated and subjected to PCR, sub-cloning and Sanger sequencing. All of the sequenced 
colonies showed mutations with a 208 bp deletion. (d) Gel electrophoresis of PCR product -using specific 
primers for PDX1- from different tissues (liver, lung, heart, kidney, muscle and spleen) of the mutant fetus. Full-
length gel is presented in the Supplementary information. (e) Protein sequence of the disrupted allele of the 
PDX1-KO sheep fetus is shown in red.
www.nature.com/scientificreports/
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Pigs and sheep are suitable models for human organ generation given their anatomical size, relatively short 
generation interval and easier handling as compared to other livestock animals. Recently, pancreatogenesis dis-
abled pigs were produced by somatic cell nuclear transfer (SCNT) using transgenic fibroblasts as donor cells8 or 
using the CRISPR/Cas9 system9. However, until now there were no publications that describe this approach in 
sheep. The sheep also has proven to efficiently form an inter-species chimera with goats23.
Generation of mutant embryos by direct CRISPR/Cas9 microinjection into zygotes is typically performed 
prior to the onset of DNA replication to ensure only two copies of DNA are present. This is only possible in 
the short window between fertilization and DNA replication, which in cattle embryos lasts around 13 hours 
post-fertilization24. When gene editing occurs after DNA replication, it can lead to mosaicism. The presence 
of multiple alleles after using CRISPR/Cas9 was previously reported in sheep14 and other species12,25. Delayed 
activity of CRISPR/Cas9 is a likely cause for mosaicism. Therefore, we tested microinjecting CRISPR/Cas9 in 
MII oocytes, giving the system more time to edit targets prior to the onset of DNA replication. Even though the 
rate of mosaicism was not different between MII oocytes and zygotes microinjection, the proportion of bi-allelic 
mutations was higher after MII oocyte microinjection.
In the present study, we observed that cytoplasmic microinjection of MII oocytes reduces the lysis rate when 
compared to microinjection of zygotes. In livestock species visualization of the pronuclei is difficult because of 
the presence of lipid droplets that make the cytoplasm opaque26. This technical issue could explain the higher 
lysis rate when injecting zygotes, due to possible damage of the pronuclei when aspirating cytoplasm to break 
the plasma membrane. Our data also indicate that CRSPR/Cas9 MII oocyte microinjection increases blastocyst 
development rates versus zygote microinjection. This result is possibly also related to the technique of zygote 
microinjection in livestock species, and a reduction in damage of nuclear DNA in MII oocytes versus zygotes.
The ultimate goal of CRISPR/Cas9 microinjection is to induce gene mutations resulting in inactive gene prod-
ucts. Frame-shift mutations are an effective way to achieve gene inactivation via small deletions or insertions gen-
erally produced after CRISPR/Cas9 activity. Furthermore, bi-allelic mutations are required to assay the phenotype 
of knockout genes. We found that while microinjecting MII oocytes or zygotes induces similar overall mutation 
rates (~59%), MII microinjection quadrupled the presence of bi-allelic mutations (12% vs. 3%). Still, while using a 
single sgRNA resulted in high mutation efficiency, PDX1 disruption is hard to predict due to in-frame mutations. 
In our study, generation of bi-allelic fetuses with in-frame mutations did not alter gene function as evidenced 
by normal pancreas development. The high frequency of in-frame mutations using the single sgRNA does not 
appear to arise from any obvious microhomologies around the mutation sites. As only one single sgRNA was 
tested extensively, it is unclear whether the high in-frame mutation rate is a property of all single sgRNAs in sheep 
(single sgRNAs in many other studies show no strong preference for in-frame mutations) or simply an aberrant 
attribute of the specific sgRNA we used. Using CRISPR/Cas9 with two sgRNAs has been shown to induce large 
Figure 5. PDX1-KO phenotype in sheep. (a) Macroscopic appearance of the vestigial pancreas of a PDX1−/− 
4-month-old male fetus compared to a WT fetus of the same age. In the right panel the dashed lines indicate 
the pancreas (WT) and the vestigial pancreas (PDX1−/−) that were isolated for histology. St.: stomach; D.: 
duodenum. (b) Histology of the pancreas. The left panel shows representative images (40X) of the pancreas 
and vestigial structure stained with hematoxylin and eosin. Insets are high magnification images (200X) to 
illustrate the lack of Langerhans islets in the PDX1−/− vestigial tissue. Right panel shows pancreatic tissue 
sections immunostained for PDX1 (green) and Insulin (red). The withe arrow indicates a PDX1 positive cell. Bar 
indicates 50 µm.
www.nature.com/scientificreports/
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gene deletions in other species9,27,28. As expected, the application of this strategy to target sheep PDX1 induced a 
large PDX1 deletion that resulted in the absence of pancreas development. Upon dissection, the area where the 
pancreas is located had a small structure with acinous-like tissue. Neither PDX1 nor insulin were detected in the 
tissue, confirming that islets were completely absent after PDX1 disruption. Our results are supported by studies 
in mice where PDX1 knockout resulted in a phenotype with the initial buds of the pancreas forming, but subse-
quent branching and morphogenesis arrested29,30. Additionally, the PDX1+/− genotype did not appear to have an 
effect on pancreas development in sheep as has been previously shown in mice31.
While we did not test for off-target effects of the CRISPR/Cas9 approach, the fact that the same gene (PDX1) 
has been previously demonstrated in other species (mouse/rats/pig) to be essential for pancreatic development 
lends strong support to the notion that the CRISPR/Cas9-mediated mutations of the PDX1 gene in the sheep 
embryos was the direct reason for the absence of the pancreas. Furthermore, given the intended use of this model 
– a host for interspecies organogenesis – off-target mutations that are not lethal/detrimental to the embryo would 
not represent a limitation for its use, as the product would be derived from the pluripotent cells and not the host 
animal.
In summary, we demonstrate that, as in other species, PDX1 disruption in sheep leads to compromised pan-
creas development. The CRISPR/Cas9 system resulted in an efficient method for knockout generation in one 
step. Injecting MII oocytes reduced lysis after microinjection and improved development compared to zygote 
microinjection. In addition, bi-allelic mutation rates were improved. Finally, using a dual sgRNA injection 
strategy resulted in an efficient method for gene disruption in sheep. Overall, injecting MII oocytes with a dual 
sgRNA system improved development and mutation efficiency in sheep. In the future, combining gene editing by 
CRISPR/Cas9 with PSC injection could provide an interesting approach for human organ generation.
Materials and Methods
Animal care. All experiments involving animals were approved and performed in accordance with the 
University of California Davis Institutional Animal Care and Use Committee (IACUC Protocol #18343) and 
Stanford University IACUC (APLAC#29980). Recipient sheep were raised at the University of California, Davis 
Sheep Unit.
General. All experiments were performed in accordance with relevant guidelines and regulations. All chem-
icals were purchased from Sigma-Aldrich Inc. unless otherwise specified.
Sheep in vitro embryo production. Ovaries were collected from an abbatoir (Superior Farms, 
Dixon, California) and transported to the laboratory in saline solution at 37 °C. Oocyte aspiration was per-
formed using a 21 G butterfly needle connected to a vacuum pump, aspirating from 2–6 mm antral follicles. 
Cumulus-oocyte-complexes (COC) were selected and in vitro maturation performed in groups of 30 COC in 
60 µl drops of TCM199 supplemented with 10% Ovine Estrus Serum (OES), oFSH (50 ng/ml; National Hormone 
& Peptide Program, UCLA, CA), bLH (3 mg/ml; Sioux Biochemical), and cysteamine (0.1 mM). COC were 
matured for 24 h in 5% CO2 with humidified atmosphere at 38.5 °C. IVF was carried out using fresh semen 
immediately diluted with Andromed (Minitube) and selected by ascendant migration with a swim-up method 
using Fertilization Medium (SOF supplemented with 2% OES, 10 µg/mL heparin, 10 µg/mL hypotaurine). COCs 
were washed twice and placed in 60 µl drops of Fertilization media. Sperm concentration was adjusted to 1 × 106 
sperm/mL and oocytes were co-incubated with the sperm for ~14 hours in 5% CO2 with humidified atmosphere 
at 38.5 C°. Putative embryos were cultured in groups of 30 in 70 µL drops of KSOM (Evolve, Zenith Biotech) with 
4 mg/mL of BSA under oil at 38.5 °C, 5% CO2 and 5% O2. Blastocysts were collected on Day 7 post-fertilization.
Sheep parthenogenetic embryo production. Oocytes were collected and matured as described for 
in vitro embryo production. After maturation, the oocytes were denuded from the surrounding cumulus cells 
by vortexing in SOF-Hepes medium containing hyaluronidase (1 mg/mL) for 4 minutes. Denuded oocytes were 
washed with SOF-Hepes and exposed to 5 µM ionomycin (Calbiochem) in SOF-Hepes for four minutes. Oocytes 
were rinsed four times and incubated four hours in 2 mM of Dimethylaminopyridine (DMAP) in KSOM. After 
the incubation, oocytes were rinsed and cultured under the same conditions described above.
sgRNA design and in vitro transcription. The single sgRNA targeting PDX1 was designed and con-
structed by Transposagen (Kentucky, USA). The dual sgRNAs were designed using an online software (MIT 
CRISPR design tool) and synthetized using a cloning-free method. The oligos containing the sgRNAs and a T7 
promoter were amplified by PCR using Q5 High-Fidelity DNA Polymerase (NEB) and purified (Macherey-Nagel). 
Guide RNA templates were used for in vitro transcription with the MEGAshortscript T7 Transcription Kit 
(Invitrogen) following the manufacturer’s instructions. sgRNA were purified using MEGAclearTM Kit 
Purification for Large Scale Transcription Reactions (Ambion) and dissolved in TE (Tris 10 mM, EDTA 0.1 mM) 
buffer for microinjection. The full nucleotide sequences of the oligos are provided in the supporting material 
(Supplementary information, Table S2). Cas9 mRNA was obtained from Sigma and diluted to 200 ng/µl using 
TE buffer.
CRISPR/Cas9 microinjection. For zygote microinjection, presumptive embryos were used ~14 h post 
insemination/activation. For MII microinjection, oocytes were denuded of COCs by vortexing in SOF-Hepes 
with 1 mg/mL of hyaluronidase for 4 min. Microinjection was performed using an inverted microscope (Nikon, 
Tokyo, Japan) fitted with micromanipulators (Narishige, Tokyo, Japan) and two hydraulic oil microinjectors 
(Eppendorf, Hamburg, Germany). Cas9 mRNA (Sigma, 100 ng/µL) and sgRNA (50 ng/µL) were mixed and 
loaded to a 5–7 µm internal diameter blunt-end micropipette. Zygotes and MII oocytes were placed in 50 µL 
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drops of SOF-Hepes supplemented with 10% of FBS, secured by a holding pipette and sgRNA and Cas9 mRNA 
were intra-cytoplasmically injected (5–10 pL) assisted by laser zona pellucida ablation (Saturn 5, RI, UK). The 
cytoplasm of the oocyte/zygote was aspirated by applying negative pressure to ensure membrane breakage32. After 
microinjection zygotes were returned to culture conditions and MII oocytes were in vitro fertilized or activated. 
All the microinjections were performed in groups of 25 and each session was limited to 30 min.
DNA preparation and genotyping of a single blastocyst. Single blastocysts were lysed with 10 µl of 
lysis buffer (Epicentre) and incubated at 65 °C for 6 minutes and 98 °C for 2 minutes. Two rounds of PCR using 
GoTaq Hot Start Green Master Mix (Promega) with specific primers for PDX1 sequences were performed. The 
PCR conditions were 95 °C for 5 min, followed by 35 cycles of 95 °C for 30 sec, 58 °C for 30 sec, 72 °C for 45 sec, 
followed by a final step of 72 °C for 10 min. PCR products were separated by gel electrophoresis, DNA bands were 
cut and purified using QIAquick Gel extraction kit (QIAGEN), and Sanger sequenced using the reverse primer 
(Quintara Biosciences). Sequences were aligned to the reference using SnapGene software. TIDE (Tracking of 
Indels by Decomposition) bioinformatics package33 was used to determine mutation efficiency. Primers for gen-
otyping are provided in supporting material (Supplementary information, Table S2).
Barcoded amplicon primer design, PCR amplification, and deep sequencing. Six different bar-
codes, each with a unique 16 bp sequence, were added to the forward and reverse primers for PDX1 gene. DNA 
from single embryos was first PCR-amplified as described above, and a second round of PCR was performed 
using the barcoded primers. PCR products were checked for size (240 bp) using gel electrophoresis and all sam-
ples with the expected size were sent for library preparation and next generation sequencing using paired-end 
reads (2 × 150 bp) at the Center of Computational & Integrative Biology at Massachusetts General Hospital. 
De-multiplexing of barcodes was performed using a custom script. FastQ reads were mapped to the Ovis aries 
Pancreatic and duodenal homeobox 1 gene (GCA_000765115.1, NCBI) using BWA. Genomic variants were 
determined using the package CrisprVariant (Version 1.4.0)34.
Sheep embryo transfer. Estrus synchronization was performed using a intravaginal progesterone device 
(0.3 g of progesterone; CIDR-G; Zoetis) for 6 days, followed injection of prostaglandin F2 (10 mg dinoprost thro-
metamine; Zoetis) and injection of PG600 (400 IU PMSG, 200 IU hCG; Intervet) coinciding with withdrawal 
of the device. Estrus detection was performed every 12 hours after CIDR-G withdrawal and embryo transfer 
was done 5 days after estrus. All the ewes were fasted for 16 hours before the procedure. Laparoscopic embryo 
transfer was performed in sedated ewes. Sedation consisted of the administration of 1.1–2.2 mg/kg of ketamine 
and 0.2-0.3 mg/kg of Midazolam 15 minutes before laparoscopy. Local anesthesia was done using 2% Lidocaine 
in the incision site. Embryos were transferred by laparoscopy (Karl Storz, Germany) to the tip of the uterine horn 
ipsilateral to the CL. Pregnancy was diagnosed 25 days after embryo transfer by transrectal ultrasonography (7.5 
MgHz, Aloka 500).
Fetus collection and genotyping. Recipient sheep were euthanized and fetuses collected at day 75 or 
120 of gestation. Samples collected from different tissues were used for genomic DNA extraction using the 
DNeasy Blood & Tissue extraction kit (QIAGEN). PCR was performed using GoTaq Hot Start Green Master 
Mix (Promega) using the same primers and conditions described above. PCR products were purified, cloned into 
pCR™TOPO®TA vector (Life Technologies) and transformed into E. Coli DH5-alpha competent cells (NEB). 
Ten colonies were picked, cultured in LB broth, and plasmid DNA was extracted using a Miniprep kit (QIAGEN). 
Fast digest EcoRI (Thermo Scientific) was used to identify the positive colonies and samples were sent for Sanger 
sequencing (Quintarabio). Sequencing analysis was performed as described above.
Histological analysis. Pancreas samples from the PDX1 wild type and PDX1-KO fetuses were fixed with 4% 
paraformaldehyde at 4 °C overnight and then embedded in paraffin using standard procedures. Samples were cut 
into 7 µm slices and stained with Hematoxylin and Eosin. For immunofluorescence, samples were dewaxed, rehy-
drated and stained using specific antibodies. The primary antibodies used were rabbit anti-PDX1 (1:250, Abcam, 
ab47267) and guinea pig anti-Insulin (1:500, Dako, A0564).
Statistical analysis. Lysis rate observed in microinjected oocytes and zygotes, in vitro embryo development 
on day 7 and the presence of mosaicism among experimental groups was analyzed by logistic regression including 
the effects of treatment and the replicate. The average number of alleles per mutated embryo was analyzed by one 
way ANOVA. Differences were considered significant when P < 0.05.
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